Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagen...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/033d27e0f2a149c69bf313f03c494de0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:033d27e0f2a149c69bf313f03c494de0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:033d27e0f2a149c69bf313f03c494de02021-11-14T09:00:14ZOptimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride2072-03512072-037810.14341/2072-0351-6017https://doaj.org/article/033d27e0f2a149c69bf313f03c494de02010-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6017https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagents of this class produce side effects (increased body mass, hypoglycemia, resistance to therapy, etc.) attributable to excess stimulation of insulinsecretion. Glimepiride is as efficient as traditionally used sulfonylureas but causes a smaller rise in insulin secretion. Sulfonylurea receptors showlower affinity for glimepiride than for glibenclamide. Formation and dissociation of glimepiride-receptor complexes occur faster than those of glibenclamide-receptor complexes. In addition, therapeutic effect of glimepiride was shown to be associated with improved insulin sensitivity. It is concludedthat glimepiride is an efficacious agent for the treatment of type 2 diabetes.Tatiana Ivanovna RomantsovaNadezhda Viktorovna MaksimovaEndocrinology Research Centrearticletreatment of type 2 diabetessulfonylureasglimepirideinsulin secretioninsulin sensitivityNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 1, Pp 50-54 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
treatment of type 2 diabetes sulfonylureas glimepiride insulin secretion insulin sensitivity Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
treatment of type 2 diabetes sulfonylureas glimepiride insulin secretion insulin sensitivity Nutritional diseases. Deficiency diseases RC620-627 Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| description |
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagents of this class produce side effects (increased body mass, hypoglycemia, resistance to therapy, etc.) attributable to excess stimulation of insulinsecretion. Glimepiride is as efficient as traditionally used sulfonylureas but causes a smaller rise in insulin secretion. Sulfonylurea receptors showlower affinity for glimepiride than for glibenclamide. Formation and dissociation of glimepiride-receptor complexes occur faster than those of glibenclamide-receptor complexes. In addition, therapeutic effect of glimepiride was shown to be associated with improved insulin sensitivity. It is concludedthat glimepiride is an efficacious agent for the treatment of type 2 diabetes. |
| format |
article |
| author |
Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova |
| author_facet |
Tatiana Ivanovna Romantsova Nadezhda Viktorovna Maksimova |
| author_sort |
Tatiana Ivanovna Romantsova |
| title |
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_short |
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_full |
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_fullStr |
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_full_unstemmed |
Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| title_sort |
optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/033d27e0f2a149c69bf313f03c494de0 |
| work_keys_str_mv |
AT tatianaivanovnaromantsova optimizationoftherapyoftype2diabetesmellituswiththeoralhypoglycemicagentglimepiride AT nadezhdaviktorovnamaksimova optimizationoftherapyoftype2diabetesmellituswiththeoralhypoglycemicagentglimepiride |
| _version_ |
1718429630700978176 |